|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:amphetamine
|
|
gptkbp:age
|
adolescents
adults
children
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:broadcastOn
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:contraindication
|
hyperthyroidism
advanced arteriosclerosis
known hypersensitivity to amphetamine products
moderate to severe hypertension
symptomatic cardiovascular disease
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:form
|
orally disintegrating tablet
12.5 mg
15.7 mg
18.8 mg
21.9 mg
3.1 mg
6.3 mg
9.4 mg
|
|
gptkbp:genericAvailable
|
no
|
|
gptkbp:indication
|
gptkb:attention_deficit_hyperactivity_disorder
|
|
gptkbp:manufacturer
|
gptkb:Neos_Therapeutics
|
|
gptkbp:mechanismOfAction
|
gptkb:stimulant
|
|
gptkbp:NDCCode
|
57962-0303-30
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:releaseYear
|
extended-release
|
|
gptkbp:riskFactor
|
sudden cardiac death
potential for abuse
dependence
psychiatric adverse events
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
anxiety
weight loss
insomnia
dry mouth
irritability
decreased appetite
increased blood pressure
|
|
gptkbp:storage
|
store at 20°C to 25°C (68°F to 77°F)
|
|
gptkbp:bfsParent
|
gptkb:Amphetamine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adzenys XR-ODT
|